Advanced search
Publication Cover
The Aging Male Volume 23, 2020 - Issue 5
Submit an article Journal homepage
6,776
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study

Aksam A. Yassina Department of Surgery, Division of Urology/Andrology & Men‘s Health, Hamad Medical Corporation, Doha, Qatar;b Weill Cornell Medical School (WCM-Q), Doha, Qatar;c Center of Medicine and Health Sciences, Dresden International University, Dresden, Germany;d Institute of Urology & Andrology, Andrology Program, Norderstedt, GermanyCorrespondence[email protected]
,
Mustafa Alwanie School of Medicine, University of Science and Technology Jordan, Irbid, Jordan
,
Riadh Taliba Department of Surgery, Division of Urology/Andrology & Men‘s Health, Hamad Medical Corporation, Doha, Qatar;b Weill Cornell Medical School (WCM-Q), Doha, Qatar
,
Yousef Almehmadid Institute of Urology & Andrology, Andrology Program, Norderstedt, Germany;f Rabigh Medical College, King Abdulaziz University, Rabigh, Saudi Arabia
,
Joanne E. Nettleshipg Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK
,
Khalid Alrumaihia Department of Surgery, Division of Urology/Andrology & Men‘s Health, Hamad Medical Corporation, Doha, Qatar;b Weill Cornell Medical School (WCM-Q), Doha, Qatar;c Center of Medicine and Health Sciences, Dresden International University, Dresden, Germany
,
Bassam Albabac Center of Medicine and Health Sciences, Dresden International University, Dresden, Germany
,
Daniel M. Kellyg Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK;h Biomolecular Research Centre, Sheffield Hallam University, Sheffield, UK
&
Farid Saadc Center of Medicine and Health Sciences, Dresden International University, Dresden, GermanyORCID Iconhttps://orcid.org/0000-0002-0449-6635
ORCID Icon show all
Pages 1553-1563 | Received 10 Aug 2020, Accepted 17 Dec 2020, Published online: 13 Jan 2021

Figures & data

Table 1. Baseline characteristics of Testosterone treatment group (T-group) and control group (C-group).

Figure 1. Total testosterone (nmol/L) in 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. *p < 0.0001 between groups.

Figure 1. Total testosterone (nmol/L) in 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. *p < 0.0001 between groups.

Figure 2. The Fatty Liver Index (FLI) in 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. *p < 0.0001 between groups.

Figure 2. The Fatty Liver Index (FLI) in 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. *p < 0.0001 between groups.

Figure 3. γ-GT (A) and bilirubin levels (B) 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. Significance indicated between groups. *p < 0.0001.

Figure 3. γ-GT (A) and bilirubin levels (B) 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. Significance indicated between groups. *p < 0.0001.

Figure 4. AST (A) and ALT (B) levels in 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. *p < 0.0001 between groups.

Figure 4. AST (A) and ALT (B) levels in 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. *p < 0.0001 between groups.

Figure 5. Triglyceride levels in 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. *p < 0.0001 between groups.

Figure 5. Triglyceride levels in 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. *p < 0.0001 between groups.

Figure 6. BMI (A) and waist circumference (B) of 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. *p < 0.0001 between groups.

Figure 6. BMI (A) and waist circumference (B) of 321 hypogonadal men on long-term treatment with testosterone undecanoate and 184 untreated hypogonadal controls. *p < 0.0001 between groups.

Table 2. Adverse events observed in testosterone treatment group (T-group) and control group (C-group).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.